@article{Tanskanen:2026:10.1039/d6pm00136j,
author = {Tanskanen, E and Sun, H and Cheng, K-C and Ishihara, J and Patel, AK},
doi = {10.1039/d6pm00136j},
journal = {RSC Pharmaceutics},
title = {Co-formulation of IL-12 mRNA and doxorubicin in polymeric nanoparticles for simultaneous delivery in murine melanoma},
url = {http://dx.doi.org/10.1039/d6pm00136j},
year = {2026}
}

Download

TY  - JOUR
AB  - Liposomal or polymeric nanoparticles have been instrumental in improving delivery of poorly soluble chemotherapeutics and those with dose limiting toxicity such as doxorubicin (DOX). More recently, nanoformulations have shown to enable simultaneous delivery of emerging biomolecules such as siRNA. However, for larger nucleic acids such as mRNA this remains challenging. In this study, we developed a poly(β-amino ester) (PBAE) based platform, capable of co-formulation of mRNA and doxorubicin into nanoparticles. To demonstrate proof of concept using therapeutically relevant cargo, immunomodulatory interleukin-12 (IL-12) was selected as a model mRNA. IL-12 is a pro-inflammatory cytokine that promotes anti-tumour immunity partly through amplifying effector cytokines such as interferon-γ (IFNγ). We found that PBAE complexed DOX and mRNA into positively charged nanoparticles of 120 nm and size-exclusion chromatography indicated a DOX  loading efficiency of over 97%.  Co-association of both DOX and mRNA was characterised at a single nanoparticle level by nano-flow cytometry. Following delivery to B16F10 murine melanoma cells, more than 95% of cells were double positive for DOX and cy5-labelled mRNA, and confocal microscopy confirmed co-localised regions of DOX with mRNA. Interestingly, nanoformulated DOX had increased nuclear accumulation by 1.7-fold relative to free DOX which correlated with a significantly reduced cell viability of 12.9% with PBAE-DOX/mRNA, compared to 26.6% for free DOX at the same dose. Moreover, despite this strong cytotoxic effect, reporter mRNA translation remained robust, with luciferase expression approximately two orders of magnitude above non-transfected controls at the highest DOX doses. Co-formulation of IL-12 mRNA and DOX with PBAE demonstrated effective IL-12 protein secretion in transfected B16F10 cells with simultaneous DOX dose dependent reduction in viability. Secreted IL-12 was bioactive, inducing dose dependent STAT4 pho
AU  - Tanskanen,E
AU  - Sun,H
AU  - Cheng,K-C
AU  - Ishihara,J
AU  - Patel,AK
DO  - 10.1039/d6pm00136j
PY  - 2026///
SN  - 2976-8713
TI  - Co-formulation of IL-12 mRNA and doxorubicin in polymeric nanoparticles for simultaneous delivery in murine melanoma
T2  - RSC Pharmaceutics
UR  - http://dx.doi.org/10.1039/d6pm00136j
UR  - https://doi.org/10.1039/d6pm00136j
ER  - 

Download